Huntingtin mitochondrial dysfunction represents one of the most well-documented and functionally significant pathological features of Huntington's disease (HD), a hereditary neurodegenerative disorder caused by an expansion of CAG trinucleotide repeats in the HTT gene encoding the huntingtin protein[@huntingtons]. The mutant huntingtin protein (mHTT) with expanded polyglutamine repeats exerts pleiotropic effects on cellular homeostasis, with mitochondria emerging as particularly vulnerable targets. Mitochondrial dysfunction in HD manifests through multiple interconnected mechanisms, including impaired respiratory chain activity, disrupted calcium homeostasis, altered dynamics (fission and fusion), and compromised quality control pathways such as mitophagy[@tabrizi2020].
The brain, with its exceptionally high energy demands and reliance on mitochondrial oxidative phosphorylation, is particularly susceptible to mitochondrial deficits. Medium spiny neurons (MSNs) in the striatum—the region most affected in HD—demonstrate some of the earliest and most severe mitochondrial impairments, contributing to their selective vulnerability[@browne2004]. Beyond the central nervous system, mitochondrial dysfunction extends to peripheral tissues, including muscle, blood cells, and fibroblasts, rendering these accessible cell types valuable for biomarker development and disease monitoring[@kim2010].
Huntingtin mitochondrial dysfunction represents one of the most well-documented and functionally significant pathological features of Huntington's disease (HD), a hereditary neurodegenerative disorder caused by an expansion of CAG trinucleotide repeats in the HTT gene encoding the huntingtin protein[@huntingtons]. The mutant huntingtin protein (mHTT) with expanded polyglutamine repeats exerts pleiotropic effects on cellular homeostasis, with mitochondria emerging as particularly vulnerable targets. Mitochondrial dysfunction in HD manifests through multiple interconnected mechanisms, including impaired respiratory chain activity, disrupted calcium homeostasis, altered dynamics (fission and fusion), and compromised quality control pathways such as mitophagy[@tabrizi2020].
The brain, with its exceptionally high energy demands and reliance on mitochondrial oxidative phosphorylation, is particularly susceptible to mitochondrial deficits. Medium spiny neurons (MSNs) in the striatum—the region most affected in HD—demonstrate some of the earliest and most severe mitochondrial impairments, contributing to their selective vulnerability[@browne2004]. Beyond the central nervous system, mitochondrial dysfunction extends to peripheral tissues, including muscle, blood cells, and fibroblasts, rendering these accessible cell types valuable for biomarker development and disease monitoring[@kim2010].
The significance of mitochondrial dysfunction in HD pathogenesis extends beyond being merely a downstream consequence of mHTT toxicity. Evidence suggests that mitochondrial impairment may represent a primary and early event in disease progression, potentially contributing to transcriptional dysregulation, synaptic dysfunction, and ultimately neuronal death[@squitieri2020]. Understanding the molecular mechanisms by which mHTT disrupts mitochondrial function therefore holds tremendous therapeutic promise.
Mutant huntingtin interacts directly with numerous mitochondrial proteins, disrupting their normal function and cellular localization. Studies have demonstrated that mHTT can bind to the outer mitochondrial membrane through interactions with proteins such as porin (VDAC) and the translocase of the outer membrane (TOM) complex[@orr2008]. This inappropriate association interferes with mitochondrial protein import, disrupt mitochondrial membrane potential, and facilitates the release of pro-apoptotic factors. The physical association of mHTT with mitochondria has been confirmed in post-mortem human brain tissue, mouse models, and cellular systems, establishing this as a fundamental pathological mechanism[@yano2014].
A hallmark of HD pathogenesis is widespread transcriptional dysregulation, with mitochondrial genes being disproportionately affected. Mutant huntingtin disrupts the function of several transcription factors critical for mitochondrial biogenesis and function, including PGC-1α (PPARGC1A), NRF-1, NRF-2, and TFAM[@cui2006]. PGC-1α, a master regulator of mitochondrial biogenesis, shows reduced expression and impaired signaling in HD models and patient tissue. The repression of PGC-1α leads to decreased expression of respiratory chain subunits, impaired mitochondrial DNA replication, and reduced mitochondrial mass—a constellation of deficits that severely compromises cellular bioenergetic capacity[@weydt2006].
Mitochondria serve as critical calcium buffers, and their ability to sequester and release calcium is essential for cellular signaling and survival. In HD, mutant huntingtin disrupts mitochondrial calcium handling through multiple mechanisms. First, mHTT alters the expression and function of mitochondrial calcium uniporter (MCU) complex components, reducing calcium uptake capacity[@brustovetsky2009]. Second, it sensitizes the mitochondrial permeability transition pore (mPTP) to opening at lower calcium thresholds, promoting cytochrome c release and apoptosis[@choo2010]. Third, altered interactions with endoplasmic reticulum (ER) mitochondria contact sites (MAMs) disrupt calcium transfer between these organelles. The resulting calcium dysregulation creates a vicious cycle where mitochondrial dysfunction contributes to further ER stress and excitotoxicity[@giacomello2020].
Mitochondria are dynamic organelles undergoing continuous cycles of fission and fusion, processes essential for mitochondrial quality control, distribution, and function. In HD, the balance between fission and fusion is dramatically disrupted. Mutant huntingtin promotes excessive fission through upregulated expression and activation of Drp1 (DNM1L), a dynamin-related GTPase that mediates mitochondrial division[@shirendeb2011]. Paradoxically, fusion proteins such as Mfn1, Mfn2, and OPA1 may be downregulated or functionally impaired. This imbalance results in fragmented mitochondria that are inefficient, unable to properly distribute throughout neuronal processes, and more prone to degradation. The disrupted dynamics further compound bioenergetic deficits and impair the ability of neurons to meet localized energy demands at synapses[@song2011].
The autophagy-lysosome pathway, particularly mitophagy—the selective removal of damaged mitochondria—is essential for maintaining mitochondrial health. Multiple steps in the mitophagy cascade are disrupted in HD. mHTT impairs autophagosome formation by interfering with ULK1 complex signaling and by sequestering key autophagy proteins into insoluble aggregates[@martinezvicente2010]. The recognition and tagging of damaged mitochondria for degradation, mediated by parkin (PRKN) and PINK1, is also compromised. PINK1 stabilization on damaged mitochondria is reduced in HD models, and parkin recruitment is impaired despite normal or elevated parkin expression[@k2020]. This failure of quality control allows accumulation of dysfunctional mitochondria that become sources of reactive oxygen species (ROS) and pro-apoptotic signals.
Mitochondrial dysfunction occupies a central position in the pathogenesis of HD, contributing to the progressive degeneration of striatal and cortical neurons. The striatum, particularly the GABAergic medium spiny neurons, exhibits some of the earliest and most dramatic pathology, with pronounced deficits in complex I and II/III of the electron transport chain[@gu1996]. These deficits lead to reduced ATP production, causing neurons to fail to maintain critical ion gradients and synaptic function. The ensuing energy failure triggers excitotoxic cascades, as the inability to maintain membrane potential leads to derepression of NMDA receptors and excessive glutamate signaling.
The progressive nature of mitochondrial dysfunction correlates with disease progression. Early premanifest individuals show subtle mitochondrial abnormalities that precede detectable neurodegeneration. As the disease advances, mitochondrial deficits become more pronounced, contributing to the characteristic neuropathological hallmarks—loss of striatal volume, cortical atrophy, and the formation of mutant huntingtin-containing inclusions[@vonsattel2014]. The selective vulnerability of striatal neurons may relate to their particularly high mitochondrial demand and their reliance on PGC-1α-mediated mitochondrial biogenesis, which is disproportionately impaired in HD.
While neurodegeneration defines the clinical phenotype of HD, mitochondrial dysfunction extends to peripheral tissues. Skeletal muscle from HD patients and mouse models shows reduced mitochondrial respiratory capacity, with decreased maximal oxygen consumption and early fatigue during exercise[@powers2013]. This peripheral mitochondrial deficit contributes to the progressive chorea and motor impairment characteristic of HD. Additionally, lymphocytes and fibroblasts from HD patients demonstrate mitochondrial abnormalities, making these accessible cell types valuable for studying disease mechanisms and testing therapeutic interventions.
Cardiac muscle also exhibits mitochondrial dysfunction in HD, with implications for the increased cardiovascular mortality observed in HD patients. Studies in mouse models reveal altered cardiac mitochondrial bioenergetics, increased ROS production, and disrupted mitophagy in the heart[@sawa2019]. These findings suggest that systemic mitochondrial dysfunction contributes to the multi-organ nature of HD, though the relative contribution of peripheral versus central mitochondrial pathology to overall disease progression remains an area of active investigation.
Mitochondrial dysfunction does not exist in isolation but interacts synergistically with other HD hallmarks. Transcriptional dysregulation, a pervasive feature of HD, both causes and results from mitochondrial impairment. Reduced PGC-1α expression decreases mitochondrial biogenesis while simultaneously disrupting nuclear-encoded gene expression more broadly. Similarly, mHTT aggregation—another pathological hallmark—may be exacerbated by mitochondrial dysfunction, as impaired energy production affects protein homeostasis systems necessary for proper mHTT clearance.
The relationship between mitochondrial dysfunction and excitotoxicity is particularly important. Normal glutamatergic signaling requires substantial ATP, and impaired mitochondrial function compromises the ability of neurons to manage calcium influx during synaptic activity. This creates a feed-forward loop where excitotoxicity further damages mitochondria, and mitochondrial failure promotes excitotoxic cell death[@beal2000]. Additionally, oxidative stress, a direct consequence of mitochondrial dysfunction, damages proteins, lipids, and DNA while also promoting mHTT aggregation and transcriptional dysregulation.
Given the centrality of mitochondrial dysfunction in HD pathogenesis, numerous therapeutic strategies targeting mitochondria have been explored. Coenzyme Q10 (CoQ10), an electron carrier in the electron transport chain and antioxidant, has been extensively studied in HD. Multiple preclinical studies demonstrated neuroprotective effects, and early clinical trials showed promising results in slowing disease progression, though larger Phase III trials have yielded mixed results[@mcgarry2020]. The inconsistent outcomes may relate to inadequate dosing, limited brain penetration, and heterogeneity in patient populations.
Mitochondrial antioxidants represent another therapeutic avenue. MitoQ, a mitochondria-targeted derivative of ubiquinone, and MitoTEMPO, a mitochondria-targeted superoxide dismutase mimetic, have shown protective effects in HD models by reducing ROS and improving bioenergetics[@liu2019]. Additionally, the compound dimebon (latrepirdine), initially developed as an antihistamine but found to have mitochondrial protective properties, underwent clinical testing in HD with some encouraging results, though subsequent trials were inconclusive[@zemlan2019].
Given the clear disruption of mitochondrial dynamics in HD, compounds that restore fission-fusion balance have attracted interest. The fission inhibitor mdivi-1, which targets Drp1, has shown neuroprotective effects in HD models by preventing excessive mitochondrial fragmentation[@kim2016]. However, long-term modulation of dynamics carries risks, as complete inhibition of fission or fusion is incompatible with normal cellular function. More refined approaches targeting specific interactions between mHTT and dynamics regulators may offer improved specificity.
Restoring the impaired PGC-1α signaling pathway represents a strategy to increase mitochondrial mass and compensate for dysfunctional existing mitochondria. The AMPK activator AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) and the SIRT1 activator resveratrol have been shown to increase PGC-1α expression and improve mitochondrial function in HD models[@chiang2012]. More specific SIRT1 activators and PGC-1α transcriptional co-activators are under development, though off-target effects and appropriate dosing remain challenges.
Emerging gene therapy technologies offer new possibilities for targeting mitochondrial dysfunction in HD. Allele-selective approaches using antisense oligonucleotides (ASOs) or RNA interference (RNAi) aim to reduce mutant huntingtin expression while sparing wild-type huntingtin, which has essential cellular functions including roles in mitochondrial maintenance[@caron2020]. Early clinical trials of HTT-targeting ASOs have demonstrated safety and tolerability, with evidence of mutant huntingtin reduction in cerebrospinal fluid, though efficacy endpoints were not met in initial studies. Beyond reducing mHTT directly, gene therapy approaches targeting mitochondrial proteins or pathways downstream of mHTT toxicity are under development.
A significant focus of current research involves identifying reliable biomarkers of mitochondrial dysfunction for use in clinical trials. MRI-based techniques measuring cerebral metabolic rates, magnetic resonance spectroscopy (MRS) assessing brain energy metabolites, and PET imaging of mitochondrial mass represent non-invasive approaches to monitor mitochondrial function in living patients[@ciammola2021]. Blood-based biomarkers, including mitochondrial DNA copy number, circulating mitochondrial RNAs, and proteins released from damaged mitochondria, offer additional possibilities for disease monitoring and treatment response assessment.
A wide range of cellular and animal models continue to advance understanding of mitochondrial dysfunction in HD. Induced pluripotent stem cell (iPSC)-derived neurons from HD patients provide human disease-relevant models demonstrating mitochondrial deficits, including impaired respiratory capacity, abnormal calcium handling, and disrupted dynamics[@ipsc2012]. These models enable testing of potential therapeutics in a patient-specific context and have revealed phenotypes not apparent in rodent models.
Transgenic mouse models, including the well-characterized R6/2, BACHD, and zQ175 lines, continue to provide insights into disease mechanisms and therapeutic testing. Recent advances include the development of conditional and region-specific models enabling dissection of the contribution of mitochondrial dysfunction in specific neuronal populations. Larger animal models, including pigs and sheep expressing mutant huntingtin, offer additional translational relevance for testing mitochondrial-targeted interventions[@yang2017].
Multiple clinical trials targeting mitochondrial dysfunction in HD are ongoing or have recently completed. The trial of pridopidine, a dopamine stabilizer with mitochondrial protective properties, demonstrated some beneficial effects on motor function in a subgroup of patients, with ongoing analyses of mitochondrial biomarkers[@waters2020]. Trials of creatine, aimed at supporting cellular energy reserves, showed some promise in earlier studies but definitive results remain pending. A Phase II trial of the mitochondrial fission inhibitor lazaroid (U-83836E) is investigating whether modulating Drp1-mediated fission can improve outcomes in HD patients.
The development of biomarkers for patient selection and response monitoring represents an important advance enabling more efficient clinical trials. The identification of mitochondrial dysfunction biomarkers that correlate with disease progression and treatment response will facilitate the transition toward personalized therapeutic approaches and enable smaller, faster trials.
Novel research directions are expanding understanding of mitochondrial dysfunction in HD. The role of mitochondrial DNA mutations and deletions in HD neurons is being explored using single-cell sequencing approaches. The contribution of astrocyte and microglial mitochondrial dysfunction to neuronal death is receiving increased attention, recognizing that non-neuronal cells play essential roles in brain energy metabolism. Additionally, the interplay between mitochondrial dysfunction and the innate immune system, particularly the activation of the NLRP3 inflammasome by mitochondrial ROS, represents a frontier in understanding neuroinflammation in HD[@martinezgomez2021].
CRISPR-based gene editing approaches offer potential for directly correcting the genetic cause of HD, with implications for preventing downstream mitochondrial dysfunction. Early preclinical studies have demonstrated successful allele-specific editing in cellular models, though delivery challenges and off-target effects remain barriers to clinical translation. The combination of gene therapy with mitochondrial-targeted small molecules represents an attractive approach that may address both the upstream cause and downstream consequences of mutant huntingtin toxicity.